Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comparison of the immunogenicity of Cervarix(®) and Gardasil(®) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cutaneous necrotic ulceration due to BCG re-vaccination

    Research output: Contribution to journalJournal articleResearch

  1. The challenges of defining sample adequacy in an era of HPV based cervical screening

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review

    Research output: Contribution to journalReviewpeer-review

  3. FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lars Toft
  • Martin Tolstrup
  • Martin Müller
  • Peter Sehr
  • Jesper Bonde
  • Merete Storgaard
  • Lars Ostergaard
  • Ole S Søgaard
View graph of relations

Individuals infected with human immunodeficiency virus (HIV) have excess risk of developing human papillomavirus (HPV)-related disease. A substantial fraction of HPV-associated cancers is caused by HPV serotypes not included in the currently available vaccines. Among healthy women, both Cervarix(®) (HPV-16/18, GlaxoSmithKline Biologicals, GSK) and Gardasil(®) (HPV-6/11/16/18, Merck) have demonstrated partial cross-protection against certain oncogenic non-vaccine HPV-types. Currently, there are no available data on vaccine-induced cross-protection in men and little is known about cross-reactive immunity after HPV-vaccination of HIV-infected individuals. In an investigator-initiated trial, we randomized 91 HIV-positive men and women to receive vaccination with Cervarix(®) or Gardasil(®). The HPV-DNA status of the participants was determined with pcr before and after immunization. Cross-reactive antibody responses against HPV-31, HPV-33, and HPV-45 were evaluated for up to 12 months using a pseudovirion-based neutralization assay (PBNA). Geometric mean antibody titers (GMTs) were compared among vaccine groups and genders at 7 and 12 months. Both vaccines induced anti-HPV-31, -33, and -45 neutralizing antibodies in participants who were seronegative and HPV-DNA negative for those types at study entry. Geometric mean antibody titers were comparable between vaccine groups. Interestingly, anti-HPV-31 and -33 antibody titers were higher among women compared with men at 7 and 12 months. In conclusion, both licensed HPV-vaccines induced cross-neutralizing antibodies against frequent oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults, and women had greater serological responses against HPV-31 and -33 compared with men.

Original languageEnglish
JournalHuman vaccines & immunotherapeutics
Volume10
Issue number5
DOIs
Publication statusPublished - 19 Feb 2014

ID: 44464908